)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shijiazhuang Yiling Pharmaceutical
Shijiazhuang Yiling Pharmaceutical (002603) investor relations material
Shijiazhuang Yiling Pharmaceutical Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary28 Oct, 2026
Executive summary
Q3 revenue was ¥1.894bn, up 3.62% YoY; net income attributable to shareholders was ¥338.6m, up 2.04%.
For 9M, revenue reached ¥5.968bn, up 1.72% YoY, while attributable net income rose 9.55% to ¥1.096bn.
Financial highlights
9M adjusted net income was ¥1.060bn, up 9.68% YoY; Q3 adjusted net income was ¥328.9m, up 1.17%.
9M non-recurring gains, net of tax and minority interests, totaled ¥35.95m; items included government grants and gains on financial assets.
9M operating cash flow increased 25.86% YoY to ¥1.609bn, primarily as sales collections increased.
Key financial ratios and metrics
9M basic and diluted EPS were both ¥0.6560, up 9.55% YoY; weighted average ROE was 9.73%, up 0.39 percentage points.
Total assets were ¥14.153bn at quarter-end, up 3.49% from year-end; equity attributable to shareholders was ¥11.249bn, up 2.37%.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shijiazhuang Yiling Pharmaceutical
- Net profit rose 13.28% to ¥757 million on stable revenue and strong cardiovascular product growth.002603
Q2 2026 - Net profit surged 25.43% year-over-year on higher revenue and robust operating cash flow.002603Q1 2026
- Net profit rose 277.56% to ¥1.29 billion on 20.24% revenue growth, with robust cash flow.002603Q4 2025
- Net profit soared 80.33% to ¥1.00 billion despite a 7.82% revenue decline.002603Q3 2025
- Net profit rose 26% to ¥669 million despite a 12% revenue drop, with strong cash flow.002603Q2 2025
- Revenue and profit declined sharply year-over-year, but operating cash flow improved.002603Q3 2024
- Revenue and profit declined sharply, but R&D and market leadership in core products remain strong.002603Q2 2024
- 2024 net loss driven by sales drop, inventory write-downs, and high R&D; cost control prioritized.002603Q4 2024
- Net profit grew 7.25% year-over-year in Q1 2025 despite a 6.52% revenue drop.002603Q1 2025
Next Shijiazhuang Yiling Pharmaceutical earnings date
Q4 202629 Apr, 2027
Shijiazhuang Yiling Pharmaceutical
Next Shijiazhuang Yiling Pharmaceutical earnings date
Q4 202629 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)